AMAsger Krog Mølgaard

Asger Krog Mølgaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Asger Krog Mølgaard has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Ismail Gögenur

    Center for Surgical Science, Department of Gastrointestinal Surgery Zealand University Hospital Køge Denmark

    3 shared publications
  • Ole Mathiesen

    Department of Anaesthesiology, Centre of Anaesthesiological Research, Zealand University, Køge, Denmark

    3 shared publications
  • Daniel Hägi-Pedersen

    Department of Anaesthesiology, Næstved, Slagelse and Ringsted Hospitals, Research Centre of Anaesthesiology and Intensive Care Medicine, Slagelse, Denmark

    2 shared publications
  • Daniel Hägi-Pedersen

    Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

    2 shared publications
  • Kasper S. Gasbjerg

    Department of Anaesthesiology, Næstved, Slagelse and Ringsted Hospitals, Research Centre of Anaesthesiology and Intensive Care Medicine, Slagelse, Denmark

    2 shared publications
  • Kasper Smidt Gasbjerg

    Centre for Anaesthesiological Research, Department of Anaesthesiology Zealand University Hospital Køge Denmark

    2 shared publications

Latest Publications

  • Open Access

    Whole Blood Transcriptomic Response to Perioperative Dexamethasone in Total Knee Arthroplasty: A Targeted Panel Analysis

    by Asger Krog Mølgaard, Kasper Smidt Gasbjerg, Lukas Balsevicius, Britt Cappelen, Adile Orhan, Helin Yikilmaz Pardes, Ole Mathiesen, Thomas Litman, Daniel Hägi‐Pedersen, Ismail Gögenur

    Background: Changes in the transcriptome of immune cells are predictive of clinical outcomes. These effects may be surgery‐specific and possibly modulated by glucocorticoids. We investigated the immune response and the impact of dexamethasone on the response in patients undergoing total knee arthroplasty (TKA). Methods: The transcript levels ( n = 579) in whole blood of 63 patients undergoing TKA and receiving either dexamethasone (DXM, n = 46) or placebo ( n = 17) perioperatively were characterised by the Nanostring nCounter platform and the Immunology V2 panel. Samples were collected before surgery and on the first postoperative day (POD1). Results: Dexamethasone induced differential expression of 113 genes (|log2 fold change| > 0.5, adjusted p ‐value [ p ‐adj] < 0.05). Pathway enrichment analysis using an Over‐Representation Analysis (ORA) indicated an up‐regulation of IL6/JAK‐STAT3‐signalling ( p ‐adj 0.016) and down‐regulation of a pathway related to allograft‐rejection ( p ‐adj 0.032). The immune response itself induced differential expression of 169 genes and ORA only found an allograft rejection pathway significant ( p ‐adj 0.016). Cell type deconvolution indicated that dexamethasone increased the granulocyte fraction (69.6% vs. 73.6%, p ‐adj = 0.005) and reduced B‐ and Plasma‐cell fraction (10.1% vs. 8.4%, p ‐adj = 0.016). The granulocyte fraction on POD1 was significantly different between dexamethasone and placebo‐treated patients (73.6% vs. 70.1%, p ‐adj = 0.048). Conclusions: Perioperative dexamethasone in TKA induced differential expression of genes related to IL6‐JAK/STAT3‐signalling as estimated by the Immunology V2 panel. This, however, is not supported by the literature or a rank‐based interpretation of the most differentially expressed genes and was most likely due to technical reasons. Future studies should focus on broader panels, different techniques or measures leading to fewer exclusions of genes during quality control when seeking to characterise the immune response to TKA and dexamethasone. Editorial Comment: This transcriptomic sub‑study shows that perioperative dexamethasone does not simply suppress, but distinctly reshapes, the early whole‑blood immune response to total knee arthroplasty. However, the study investigated an early postoperative snapshot after a single perioperative dose only. Thus, longitudinal linkage to circulating biomarkers of inflammation and injury as well as clinical outcomes could not be assessed. This study therefore should be regarded as hypothesis‑generating, urging for extended, multi‑modal and outcome‑oriented studies before concluding on the broader clinical effects of perioperative dexamethasone.

  • Open Access

    Dexamethasone vs. placebo modulation of the perioperative blood immune proteome in patients undergoing total knee arthroplasty

    by Asger K. Mølgaard, Kasper S. Gasbjerg, Ole Mathiesen, Daniel Hägi-Pedersen, Ismail Gögenur

    Pre- and post-operative immune status has gained interest in recent years, as it has been shown to be related to postoperative complications and recovery. The change in immune status has also been known to constitute a large part of the surgical stress response, and it has been speculated that immunomodulatory treatment by glucocorticoids may impact it. Profiling of the impact of specific surgeries and medications on immune status are therefore needed. We characterized the postoperative blood immune proteome in 83 patients receiving either placebo (n = 20) or IV 24 mg dexamethasone (n = 60) preoperative before total knee arthroplasty (TKA). The primary outcome was the effect of dexamethasone on total knee arthroplasty surgical stress by comparing postoperative immune proteome in the dexamethasone group and the placebo group. Secondary outcomes were the surgical stress by total knee arthroplasty by comparing pre- to postoperative immune proteome in the placebo group, and the combined effect of surgical stress and dexamethasone by comparing pre- to postoperative immune proteome in the dexamethasone group. Characterization was performed with the Olink Explorer Inflammation panel on blood samples from the biobank for future research collected during the randomized, clinical DEX-2-TKA Trial. Protein change was reported as log2-fold-change and p-values were corrected a.m. Benjamini-Hochberg. The surgical stress (placebo) was characterized by a 4.7 log2-fold-change of IL6 (adjusted p-value < 0.01) and up-regulation of central immune signaling pathways and bone marrow mobilization. The combined effect of surgery and dexamethasone showed a less pro-inflammatory profile: IL6 2.5 log2-fold-change (adjusted p-value < 0.01), with decreased signaling for osteoclast activity and innate, immune cell reaction. The effect of dexamethasone showed upregulation of CSF3 (1.55 log2-fold-change, adjusted p-value < 0.01) and an inhibitory effect on both innate and adaptive immune response, immune cell reactivity and formation of extracellular matrix. Preoperative dexamethasone indicated anti-inflammatory properties on both innate and adaptive immune response, while surgery was pro-inflammatory. the combination of total knee arthroplasty and dexamethasone inhibited pathways for osteoclast-activity, indicating possible implications on aseptic prosthesis loosening. Dexamethasone showed strong modulation of the surgical stress response following total knee arthroplasty and future studies must explore the clinical associations of these findings. NCT03506789.


  • Effect of Dexamethasone on Myocardial Injury After Total Knee Arthroplasty: A Substudy of the Randomized Clinical DEX-2-TKA Trial

    by Asger K. Mølgaard, Kasper S. Gasbjerg, Christian S. Meyhoff, Troels H. Lunn, Janus C. Jakobsen, Ismail Gögenur, Ole Mathiesen, Daniel Hägi-Pedersen